Marked species differences in the bioavailability of midazolam in cynomolgus monkeys and humans

References

• Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clinical Pharmacology and Therapeutics 1981; 30: 653–661
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, Fisher V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug–drug interaction studies: A pharmaceutical research and manufactures of America (PhRMA) perspective. Drug Metabolism and Disposition 2003; 31: 815–832
   PubMed Web of Science ®Google Scholar
• Bohers H, Annaert P, Mannens G, Van Beijsterveldt L, Anciaux K, Verboven P, Meuldermans W, Lavrijsen K. Strategies for absorption screening in drug discovery and development. Current Topics in Medicinal Chemistry 2001; 1: 367–383
   PubMedGoogle Scholar
• Chalasani N, Gorski JV, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: Effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001; 34: 1103–1108
   PubMed Web of Science ®Google Scholar
• Chiou WL, Buehler PW. Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharmaceutical Research 2002; 19: 868–874
   PubMed Web of Science ®Google Scholar
• Dreyfuss J, Shaw JM, Ross JJ. Absorption of the β-adrenergic-blocking agent, nadolol, by mice, rats, hamsters, rabbits, dogs, monkeys and man: An unusual species difference. Xenobiotica 1978; 8: 503–508
   PubMed Web of Science ®Google Scholar
• Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochemical Pharmacology 1994; 47: 1643–1653
   PubMed Web of Science ®Google Scholar
• Hayes A, Cooper RG. Studies on the absorption, distribution and excretion of propranolol in rat, dog and monkey. Journal of Pharmacology and Experimental Therapeutics 1971; 176: 302–311
   PubMed Web of Science ®Google Scholar
• Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. British Journal of Clinical Pharmacology 1983; 16(Suppl.)43S–49S
   Google Scholar
• Heizmann P, Ziegler WH. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittel-Forshung 1981; 31: 2220–2223
   PubMed Web of Science ®Google Scholar
• Jacqz E, Billante C, Moysan F, Mathieu H. The non-human primate: A possible model for human genetically determined polymorphisms in oxidative drug metabolism. Molecular Pharmacology 1988; 34: 215–217
   PubMed Web of Science ®Google Scholar
• Kato M, Chiba K, Hisaka A, Ishigami M, Kayama M, Mizuno N, Nagata Y, Takakuwa S, Tsukamoto Y, Ueda K, Kusuhara H, Ito K, Sugiyama Y. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein—quantitative analysis based on information from the literature. Drug Metabolism and Pharmacokinetics 2003; 18: 365–372
   PubMedGoogle Scholar
• Komori M, Kikuchi O, Kitada M, Kamataki T. Molecular cloning of monkey P450 1A1 cDNA and expression in yeast. Biochimica et Biophysica Acta 1992a; 1131: 23–29
   PubMed Web of Science ®Google Scholar
• Komori M, Kikuchi O, Sakuma T, Funai J, Kitada M, Kamataki T. Molecular cloning of monkey liver cytochrome P-450 cDNAs: Similarity of the primary sequences to human cytochromes P-450. Biochimica et Biophysica Acta 1992b; 1171: 141–146
   PubMed Web of Science ®Google Scholar
• Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology 1989; 36: 89–96
   PubMed Web of Science ®Google Scholar
• Mandema JW, Tuk B, Van Steveninck AL, Breimer DD, Cohen AF, Danhof M. Pharmacokinetic–pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clinical Pharmacology and Therapeutics 1992; 51: 715–728
   PubMed Web of Science ®Google Scholar
• Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, Lawton MP. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Archives of Biochemistry and Biophysics 1999; 372: 189–196
   PubMed Web of Science ®Google Scholar
• McKinnon RA, Burgess WM, Hall PM, Roberts-Thomson SJ, Gonzalez FJ, McManus ME. Characterisation of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 1995; 36: 259–267
   PubMed Web of Science ®Google Scholar
• Reeves PR, Barnfield DJ, Longshaw S, McIntosh DAD, Winrow MJ. Disposition and metabolism of atenolol in animals. Xenobiotica 1978; 8: 305–311
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 2002; 35: 1549–1551
   PubMed Web of Science ®Google Scholar
• Rowland KY, Rostami-Hodjegan A, Tucker GT. Abundance of cytochromes P450 in human liver: A meta-analysis. British Journal of Clinical Pharmacology 2004; 57: 687–688
   Google Scholar
• Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L. Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. Journal of Pharmacy and Pharmacology 2001; 53: 1007–1013
   PubMed Web of Science ®Google Scholar
• Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Smith MT, Eadie MJ, O’Rourke Brophy T. The pharmacokinetics of midazolam in man. European Journal of Clinical Pharmacology 1981; 19: 271–278
   PubMed Web of Science ®Google Scholar
• Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, Wilkinson GR. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clinical Pharmacology and Therapeutics 1996; 59: 491–502
   PubMed Web of Science ®Google Scholar
• Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Hartwell PS, Raisys VA, Marsh CL, McVicar JP, Barr DM, Perkins JD, Carithers RL. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro–in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics 1994; 271: 549–556
   PubMed Web of Science ®Google Scholar
• Tsunoda SM, Velez RL, Von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics 1999; 66: 461–471
   PubMed Web of Science ®Google Scholar
• Wrighton SA, Ring BJ. Predicting drug interactions and pharmacokinetic variability with in vitro methods: The olanzapine experience. Drug Metabolism Reviews 1999; 31: 15–28
   PubMed Web of Science ®Google Scholar